A Meta-analysis of intradermal versus intramuscular influenza vaccines: Immunogenicity and Adverse Events

Influenza and other Respiratory Viruses

Volumn 7, Issue 4, 2013, Pages 584-603

  Marra, Fawziah ^a,b   Young, Flora ^c   Richardson, Kathryn ^a   Marra, Carlo A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c FRASER HEALTH AUTHORITY   (Canada)

Author keywords

Influenza vaccine; Intradermal; Meta analysis; Route of administration

Indexed keywords

INFLUENZA VACCINE;

AGE; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; CHILL; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG SAFETY; ECCHYMOSIS; ERYTHEMA; FEVER; GEOMETRIC MEAN TITER RATIO; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; MALAISE; META ANALYSIS; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PAIN; PARAMETERS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SEROCONVERSION; SHIVERING; STATISTICAL SIGNIFICANCE; SWELLING; SYSTEMATIC REVIEW; VIRUS STRAIN;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG TOXICITY; FEMALE; HUMANS; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84879107194     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12000     Document Type: Article

References (30)

1. Dolin R. Chapter 180. Influenza; in Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J (eds): Harrison's Principles of Internal Medicine, 17e: http://www.accessmedicine.com/content.aspx?aID=2895663 (Accessed 03 March 2011).
2. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-186.
3. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2007; 7:CD001269.
4. Ginaldi L, Loreto MF, Corsi MP, Modesti M, Martinis MD. Immunosenescence and infectious diseases. Microbes Infect 2001; 3:851-857.
5. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-1169.
6. Deans GD, Stiver HG, McElhaney JE. Influenza vaccines provide diminished protection but are cost-saving in older adults. J Intern Med 2010; 267:220-227.
7. McElhaney JE, Dutz JP. Better influenza vaccines for older people: what will it take?J Infect Dis 2008; 198:632-634.
8. McElhaney JE, Zhou X, Talbot HK et al. The unmet need in the elderly: how immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. Vaccine 2012; [E-pub ahead of print].
9. Young F, Marra F. A systematic review of intradermal influenza vaccines. Vaccine. 2011; 29:8788-8801.
10. European Agency for the Evaluation of Medicinal Products. Note for guidance on harmonization of requirements for influenza vaccines. 12 March 1997. Available at: http://www.ema.europa.eu/pdfs/human/bwp/021496en.pdf [Accessed 21 June 2010].
11. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PlosMedicine. 2009; 6:e1000100.
12. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5. Chester, England: Wiley-Blackwell, 2008.
13. Jadad AR, Moore RA, Carroll D et al. Assessing quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials 1996; 17:1-12.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Contr Clin Trials 1986; 7:177-188.
15. Beran J, Ambrozaitis A, Laiskonis A et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med 2009; 7:13.
16. Arnou R, Eavis P, Pardo JR, Ambrozaitis A, Kazek MP, Weber F. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60years: randomized, controlled, phase III trial. Hum Vaccin 2010; 6:346-354.
17. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 2009; 27:454-459.
18. Leroux-Roels I, Vets E, Freese R et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomised controlled safety and immunogenicity trial in adults. Vaccine 2008; 26:6614-6619.
19. Belshe RB, Newman FK, Wilkins K et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 2007; 25:6755-6763.
20. Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007; 25:659-663.
21. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. New Engl J Med. 2004; 351:2295-2301.
22. Van Damme P, Arnou R, Kafeja F et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect Dis 2010; 10:134.
23. Chi RC, Rock MT, Neuzil KM. Immunogenicity and safety of intradermal influenza vaccination in healthy older adults. Clin Infect Dis 2010; 50:1331-1338.
24. Arnou R, Icardi G, De Decker M et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009; 27:7304-7312.
25. Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198:650-658.
26. Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. New Engl J Med 2004; 351:2286-2294.
27. Chuaychoo B, Wongsurakiat P, Nana A, Kositanont U, Maranetra KN. The immunogenicity of intradermal influenza vaccination in COPD patients. Vaccine 2010; 28:4045-4051.
28. Keitel WA, Atmar RL, Cate TR et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-1127.
29. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999; 17(Suppl1):S3-S10.
30. McElhaney JE. Influenza vaccine responses in older adults. Ageing Res Rev 2001; 10:379-388.